<DOC>
	<DOC>NCT01487811</DOC>
	<brief_summary>This trial is conducted in the United states of America (USA). The aim of this trial is to compare two formulations of biphasic insulin aspart 30 in healthy volunteers.</brief_summary>
	<brief_title>Comparison of Two Biphasic Insulin Aspart 30 Formulations (Current and New Formulation) in Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec, insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin aspart, insulin aspart protamine drug combination 30:70</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Biphasic Insulins</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin, Long-Acting</mesh_term>
	<mesh_term>Insulin, Isophane</mesh_term>
	<criteria>BMI (body mass index) between 18 and 28 kg/m^2, both inclusive Subject is a nonsmoker for at least 3 months Subject is judged to be in good health on the basis of their medical history, physical examination, ECG (electrocardiogram), and routine laboratory data Fasting plasma glucose between 80 and 110 mg/dl •Any clinically significant disease history of systemic or organ disease •Clinically significant abnormalities on prestudy clinical examination or any laboratory measurements during screening (any abnormality should be discussed with the clinical monitor) •In females of child bearing potential: Pregnancy, lactating, breastfeeding, intent to become pregnant within the next 6months or judged to be using inadequate contraceptive measures (adequate contraceptive measures include: condom, intrauterine devices). ßhCG pregnancy test must be negative</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>